🔗 Share this article

Given that the United States undertakes sweeping changes to its vaccination guidelines, one figure has emerged unexpectedly: Høeg, a US-based sports medicine doctor and epidemiologist who rose to prominence by questioning Covid vaccines in the pandemic and has concentrated on potential deaths after COVID-19 vaccination in her recent tenure at the Food and Drug Administration.

Planned Overhauls to Childhood Immunization Program

Public health authorities had intended to unveil sweeping revisions to the pediatric immunization program earlier this month, synchronizing the US with the Danish vaccine program, sources say – a substantial departure that would put the US at odds with much of the global community with little proof for improved outcomes. The planned update has been pushed back until the coming year.

Rather than the top vaccines chief, Dr. Høeg is scheduled to present at the gathering. She was just designated interim head of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth appointee to run the division this calendar year.

A Shift at the Agency

This interim role might represent a closer partnership between the pharmaceutical and vaccine divisions as Dr. Høeg and Prasad strengthen their influence at the regulatory agency – and it suggests a greater focus upon dismantling long-standing immunizations at the FDA.

Høeg has repeatedly called for discontinuing some pediatric shot schedules in the US so as to align more similar to Denmark, a country with nationalized medicine and a population approximately the size of the state of Wisconsin.

To date public appearances, she has persisted in emphasizing on immunizations – typically the domain of Dr. Prasad, chief of the FDA’s Center for Biologics Evaluation and Research (CBER) – as opposed to pharmaceutical oversight.

Concerns Over Qualifications

Høeg has no obvious track record in medication creation, oversight or leadership, which has been standard for past leaders of the biologics center. She has served at the FDA as a key advisor to the commissioner and CBER since earlier this year.

“She doesn’t seem to have the requisite experience” for leading the CDER, remarked a neurologist and psychiatrist. “She has not conducted a clinical trial. She lacks experience in managing a large organization. She lacks background in drug approvals.”

Former directors of CBER would “grasp legal statutes and the research of drug development”, commented Janet Woodcock. “Frankly, she lacks the sort of resume that prior appointees who led CBER have had.”

CDER has an immense workload at the FDA, Woodcock stated.

“Everybody just zeroes in on the innovative therapies, but the generic program approves numerous generic medications. There’s a biosimilars program, OTC medication office and more, and all of those need to be looked after,” Dr. Woodcock explained. “The responsibility you overlook, that is precisely what that I always told people is going to come back to haunt you.”

Furthermore, a substantial administrative element to the job, which supervises more than 5,000 staff members. “It is a massive leadership role, if you perform it correctly,” the former official added.

Response and Disputed Policies

In response to concerns about Dr. Høeg's qualifications and whether this appointment represents increased cooperation among agency officials on vaccines, a spokesperson responded that the “concerns rely on inaccurate assumptions”.

“This background matches the functions of her position,” the representative said, citing the months Høeg spent counseling the FDA commissioner on “medication safety and regulatory science, including predictive safety algorithms and vaccine surveillance”.

As acting director, Høeg takes over the agency head's recently launched priority voucher program, a disputed rapid drug-approval program that allegedly troubled her preceding directors. “By what process are these medications being selected for this expedited pathway? Who is making the decisions?” Howard asked. “There is a lot of confidentiality happening at the agency right now.”

In general, he said, “the FDA looks to be trending towards more relaxed oversight of pharmaceuticals, with the exception of immunizations.”

Public Past Work on Immunizations

With immunizations, Høeg has a more documented, if concerning, history, some experts said. She released a research paper using unverified volunteer-provided data to estimate the incidence of heart inflammation following COVID-19 immunization. She counseled the state of Florida surgeon general Joseph Ladapo, who allegedly have altered data to suggest COVID-19 vaccinations are pose a greater threat than they are.

Included in her “policy goals” for the current government encompassed changing regulations for new vaccines and ending “optional” immunizations, she stated post-election on a audio program. At the agency, Høeg has reportedly proposed excluding teenage boys from obtaining Covid vaccinations.

“She is an thorough ideologue who starts off with her preconceived notions and works backwards to accommodate the data in a highly disingenuous, untruthful manner,” Dr. Howard stated.

Consolidating Power and a “Campaign of Retribution”

Høeg joined other dissenters, {like|